|
Cytochrome-c Oxidase Deficiency
|
0.640 |
GeneticVariation
|
disease |
BEFREE |
In the following article, the phenotypes of the two Ptgs (genes coding for COX-1 and COX-2) knockouts are summarized, and recent studies to investigate the effects of COX deficiency on cancer susceptibility, inflammatory response, gastric ulceration, and female reproductive processes are discussed.
|
10487525 |
1999 |
|
Cytochrome-c Oxidase Deficiency
|
0.640 |
GeneticVariation
|
disease |
UNIPROT |
A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy.
|
10486321 |
1999 |
|
Cytochrome-c Oxidase Deficiency
|
0.640 |
GeneticVariation
|
disease |
BEFREE |
Despite mitochondrial proliferation and transcriptional upregulation of nuclear and mtDNA-encoded COX genes (including MT-CO2), a severe COX deficiency was found with all investigations of the muscle biopsy (histochemistry, biochemistry, immunoblotting).
|
18245391 |
2008 |
|
MELAS Syndrome
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
High prevalence of the COII/tRNA(Lys) intergenic 9-bp deletion in mitochondrial DNA of Taiwanese patients with MELAS or MERRF syndrome.
|
15965049 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
No significant liver cancer and colorectal cancer risk of COX-2 -765G/C polymorphism was found.
|
24969885 |
2014 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Individuals diagnosed with colorectal cancer who carry a COX-2 C(-765) allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type (G(-765)).
|
19075598 |
2008 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
COX-2 and BCRP polymorphisms were not associated with CRC risk.
|
19930591 |
2009 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetically determined low COX-2 and high IL-1β activity were associated with increased risk of CRC in this northern Caucasian cohort.
|
24194923 |
2013 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we sought to understand the role of three COX-2 polymorphisms (-1195A>G, -765G>C, and 8473T>C) in colorectal cancer (CRC) onset.
|
20075740 |
2010 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We analyzed in Spanish population the risk contribution and the prognostic significance for colorectal cancer (CRC) with five polymorphisms (rs20417, rs20426, rs5276, rs13306035 and rs4648298) located in the coding and regulatory regions of COX2.
|
19468846 |
2009 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk.
|
19777615 |
2009 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of the COX-2 -1195AA genotype may protect against risk of developing colorectal cancer.
|
25835114 |
2015 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis of the association between COX-2 polymorphisms and risk of colorectal cancer based on case-control studies.
|
24733273 |
2014 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
On the other hand in our study, there was no significant association between genotype distribution of the COX2 polymorphism and colorectal cancer; p=0.847.
|
24998576 |
2014 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Similarly, the increased risk for CRC was also associated with the COX-2 -765GC genotype (adjusted OR = 1.73, 95% CI = 1.23-2.43) compared with the -765GG genotype.
|
17151091 |
2007 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although these nonsteroidal anti-inflammatory drugs (NSAIDs) are often associated with gastrointestinal toxicity, there is renewed interest in their use as colorectal cancer (CRC) chemopreventive agents due to the adverse side effects associated with long-term use of selective COX-2 inhibitors.
|
21205744 |
2011 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
No interaction between use of NSAIDs and PTGS-2 (encoding COX-2) in relation to CRC risk was detected.
|
24889212 |
2014 |
|
Depressive disorder
|
0.470 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism -765 G/C in COX-2-encoding gene promoter is associated with development of Alzheimer's disease, depression, carcinoma of the pancreas in smokers, breast cancer and rheumatoid arthritis.
|
21655952 |
2012 |
|
Mental Depression
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism -765 G/C in COX-2-encoding gene promoter is associated with development of Alzheimer's disease, depression, carcinoma of the pancreas in smokers, breast cancer and rheumatoid arthritis.
|
21655952 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
In our study, we aimed to investigate the relationship between variants of COX-2 gene which is one of the key components of the inflammatory pathway, and T2DM risks.
|
30293595 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Patients who have OA and T2DM receiving combination COX-2 inhibitors and metformin therapy associated with lower joint replacement surgery rates than those without and this may be attributable to combination therapy much more decrease pro-inflammatory factors associated than those without metformin therapy.
|
29385156 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Cox proportional hazard regression analysis revealed the lower rate of admission for subjects under combination therapy (adjusted hazard ratio of 0.275; 95% confidence interval = 0.136-0.557, P < .001).Patients with RA and T2DM receiving the combination of COX-2 inhibitors and metformin were associated with lower admission rate than those on COX-2 inhibitors alone, and this effect may be attributed to the decrease in the levels of proinflammatory factors.
|
31593087 |
2019 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The most common adverse reactions are: gastrointestinal (COX1) which have declined over time with the emergence of more COX1 sparing drugs and gastroprotection; renal, with an impact on renal function and sodium extraction that is associated with hypertension, heart failure exacerbation, and stress-related renal failure; allergic skin reactions; increased transaminases and acute liver injury which may be idiosyncratic or immunoallergic; increased risk of acute coronary syndromes, initially associated with high-dose long-term use of COX2 specific inhibitors in controlled clinical trials, though more recently there have been indications from poorly controlled observational studies that they could occur with most NSAIDs.
|
30477749 |
2019 |
|
Diabetes Mellitus
|
0.160 |
GeneticVariation
|
group |
BEFREE |
To determine the association between polymorphism c.1-765G>C of the COX2 gene and cognitive impairment in elderly adults with diabetes.
|
24342014 |
2014 |